Skip to main content
. 2026 May 13;20(1):2025-0153. doi: 10.5797/jnet.ra.2025-0153

Table 3. Current clinical indications for MMAE according to disease stage (de novo vs. recurrent) and clinical severity.

Clinical severity De novo CSDH Recurrent CSDH
Severe (emergent) Surgery is first-line
(adjunct MMAE may be considered electively after stabilization; evidence is limited)
Symptomatic Adjunct MMAE is reasonable in selected high-recurrence–risk patients Adjunct MMAE should be considered
Mild symptomatic Stand-alone MMAE can be considered
Asymptomatic Conservative management is first-line (consider MMAE if large/progressive)
Not a surgical candidate/surgery contraindicated Consider stand-alone MMAE

CSDH, chronic subdural hematoma; MMAE, middle meningeal artery embolization